Pipeline: Investigational Therapies for COVID-19
Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.
Emerging Treatments
Bezlotoxumab Effective for Treating Recurrent Clostridioides difficile Infection
Bezlotoxumab, both alone and in combination with actoxumab, was effective in preventing recurrent Clostridioides difficile infection without increased risk for adverse events.
Tobramycin/Dexamethasone Suspension Available for Inflammatory Eye Conditions With Bacterial Infection
Tobradex ST contains tobramycin, an antibacterial drug, and dexamethasone, a potent corticosteroid.
Exebacase Gains Breakthrough Therapy Status for MRSA Bacteremia, Including Right-Sided Endocarditis
Exebacase is a novel, recombinantly-produced lysin (cell wall hydrolase enzyme), that targets the peptidoglycan cell wall.
Investigational Antibiotic Gets Orphan Drug Status for Pulmonary Exacerbations of Cystic Fibrosis
The FDA has granted Orphan Drug designation to ARV-1801 (sodium fusidate; Arrevus) for the treatment of pulmonary exacerbations in patients with cystic fibrosis.
Novel Cephalosporin Now Available for Treatment of Complicated UTI
Fetroja® (cefiderocol) has been made available by Shionogi for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
Early Bactericidal Activity of High-Dose Isoniazid for Drug Resistant TB
Daily doses of 10 to 15 mg/kg isoniazid demonstrated similar activity against tuberculosis (TB) strains with inhA mutations as 5 mg/kg doses against drug-sensitive strains.
Recarbrio Gets Priority Review for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
The FDA has accepted for review a sNDA for Recarbrio™, to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Nebulized Normal Saline Evaluated for Acute Viral Bronchiolitis
Nebulized normal saline, which is often used as a placebo in clinical trials evaluating therapies for acute viral bronchiolitis, may be an active treatment for this condition.
Long-Duration Vancomycin May Reduce Recurrence of Clostridioides difficile
The study researchers concluded that when compared with short-duration vancomycin therapy for the treatment of CDI, long-duration vancomycin therapy was associated with significantly lower CDI recurrence rates.
Next post in GI Illness
